Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D.

Nat Med. 2019 Dec 2. doi: 10.1038/s41591-019-0654-5. [Epub ahead of print]

PMID:
31792460
2.

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.

Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW.

J Immunother Cancer. 2019 Nov 15;7(1):307. doi: 10.1186/s40425-019-0796-5.

3.

Targeting tumor-resident mast cells for effective anti-melanoma immune responses.

Kaesler S, Wölbing F, Kempf WE, Skabytska Y, Köberle M, Volz T, Sinnberg T, Amaral T, Möckel S, Yazdi A, Metzler G, Schaller M, Hartmann K, Weide B, Garbe C, Rammensee HG, Röcken M, Biedermann T.

JCI Insight. 2019 Oct 3;4(19). pii: 125057. doi: 10.1172/jci.insight.125057.

4.

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.

Weide B, Eigentler T, Catania C, Ascierto PA, Cascinu S, Becker JC, Hauschild A, Romanini A, Danielli R, Dummer R, Trefzer U, Elia G, Neri D, Garbe C.

Cancer Immunol Immunother. 2019 Sep;68(9):1547-1559. doi: 10.1007/s00262-019-02383-z. Epub 2019 Sep 3.

PMID:
31482307
5.

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.

Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Eigentler T, Wagner NB, Uslu U, Terheyden P, Meier F, Garbe C, Pawelec G, Weide B, Wistuba-Hamprecht K.

PLoS One. 2019 Aug 16;14(8):e0221301. doi: 10.1371/journal.pone.0221301. eCollection 2019.

6.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
7.

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.

Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B.

Cancer Immunol Immunother. 2018 Dec;67(12):1845-1851. doi: 10.1007/s00262-018-2244-7. Epub 2018 Sep 14.

PMID:
30218171
8.

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Simon B, Wiesinger M, März J, Wistuba-Hamprecht K, Weide B, Schuler-Thurner B, Schuler G, Dörrie J, Uslu U.

Int J Mol Sci. 2018 Aug 11;19(8). pii: E2365. doi: 10.3390/ijms19082365.

9.

Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions.

Forschner A, Keim U, Hofmann M, Spänkuch I, Lomberg D, Weide B, Tampouri I, Eigentler T, Fink C, Garbe C, Haenssle HA.

Br J Dermatol. 2018 Aug;179(2):478-485. doi: 10.1111/bjd.16565. Epub 2018 Jun 7.

PMID:
29569229
10.

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Zeiner PS, Zinke J, Kowalewski DJ, Bernatz S, Tichy J, Ronellenfitsch MW, Thorsen F, Berger A, Forster MT, Muller A, Steinbach JP, Beschorner R, Wischhusen J, Kvasnicka HM, Plate KH, Stefanović S, Weide B, Mittelbronn M, Harter PN.

Acta Neuropathol Commun. 2018 Mar 1;6(1):18. doi: 10.1186/s40478-018-0521-5.

11.

Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.

Walz JS, Kowalewski DJ, Backert L, Nelde A, Kohlbacher O, Weide B, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Leuk Lymphoma. 2018 Aug;59(8):1949-1958. doi: 10.1080/10428194.2017.1403022. Epub 2018 Jan 3.

PMID:
29295645
12.

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.

Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, Ugurel S, Slynko A, Gutzmer R; German Dermatooncology Group (DeCOG/ADO).

Cancer Med. 2018 Jan;7(1):95-104. doi: 10.1002/cam4.1267. Epub 2017 Dec 20.

13.

Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.

Gaiser MR, Skorokhod A, Gransheier D, Weide B, Koch W, Schif B, Enk A, Garbe C, Bauer J.

PLoS One. 2017 Nov 27;12(11):e0188602. doi: 10.1371/journal.pone.0188602. eCollection 2017.

14.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

15.

Durch Pembrolizumab verursachte Hepatitis: Diagnose und Behandlung.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037_g. No abstract available.

PMID:
28872244
16.

Pembrolizumab-induced hepatitis: diagnosis and treatment.

Forschner A, Schraml C, Pierchalla K, Weide B, Eigentler TK, Lauer UM, Garbe C.

J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935. doi: 10.1111/ddg.13037. No abstract available.

PMID:
28872228
17.

Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Eigentler TK, Keim U, Goebeler M, Fiedler E, Schuler G, Leiter U, Weide B, Grischke EM, Martus P, Garbe C.

J Invest Dermatol. 2017 Dec;137(12):2570-2577. doi: 10.1016/j.jid.2017.07.006. Epub 2017 Jul 21.

18.

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

Brüggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, Croner RS, Krähenbühl L, Kähler KC, Hafner C, Leisgang W, Kiesewetter F, Dummer R, Schuler G, Stürzl M, Heinzerling L.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1977-1984. doi: 10.1007/s00432-017-2450-2. Epub 2017 Jun 14.

PMID:
28616701
19.

Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kähler KC, Gesierich A, Meissner M, von Bubnoff D, Göppner D, Schlaak M, Pföhler C, Utikal J, Heinzerling L, Cosgarea I, Engel J, Eckel R, Martens A, Mirlach L, Satzger I, Schubert-Fritschle G, Tietze JK, Berking C.

Eur J Cancer. 2017 Aug;81:36-44. doi: 10.1016/j.ejca.2017.05.014. Epub 2017 Jun 7.

PMID:
28600969
20.

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A.

Nat Commun. 2017 May 31;8:15440. doi: 10.1038/ncomms15440.

Supplemental Content

Loading ...
Support Center